ANI Pharmaceuticals (ANIP) Price & Analysis

Compare

318 Followers

ANIP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$52.50 - $99.50

Previous CloseN/A

Volume18.69K

Average Volume (3M)476.61K

Market Cap

$2.06B

Enterprise Value$1.75B

Total Cash (Recent Filing)$217.80M

Total Debt (Recent Filing)$320.08M

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Nov 05, 2025

EPS Estimate

1.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.80

Shares Outstanding21,688,772

10 Day Avg. Volume346,177

30 Day Avg. Volume476,614

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue2.34

Enterprise Value/Gross Profit4.04

Enterprise Value/Ebitda18.51

Forecast

1Y Price Target

$103.50

Price Target Upside10.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Financial PerformanceANIP delivered a record quarter, highlighted by Cortrophin Gel outperformance and a strong guidance raise on top- and bottom-line.

Market PotentialThe addressable market for Cortrophin Gel is larger than previously modeled, offering significant growth opportunities.

Product LaunchThe launch of the pre-filled syringe for Cortrophin Gel is resonating with both physicians and patients, contributing significantly to growth.

Bears Say

Market SkepticismInvestors wonder if the $97-103M guide for Iluvien is optimistic given 1H25 revenues of $38M and weakness in the ophthalmology buy-and-bill market.

ANI Pharmaceuticals News

ANI Pharmaceuticals price target raised to $115 from $95 at JPMorgan

JPMorgan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $115 from $95 and keeps an Overweight...

2d ago

ANIP

ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $121 from $93...

9d ago

ANIP

ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $114 from $86 and...

18d ago

ANIP

Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion

Analyst Ekaterina Knyazkova from J.P. Morgan maintained a Buy rating on ANI Pharmaceuticals and increased the price target...

2d ago

ANIP

ANI Pharmaceuticals Highlights Commercialization Focus Amid Challenges

The latest announcement is out from ANI Pharmaceuticals ( ($ANIP) ). ANI Pharmaceuticals‘ recent investor presentation highlights the...

18d ago

ANIP

ANI Pharmaceuticals’ Record Earnings and Optimistic Outlook

Ani Pharmaceuticals (($ANIP)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

ANIP

ANI Pharmaceuticals price target raised to $77 from $65 at Truist

Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $77 from $65 but keeps a Hold...

2M ago

ANIP

ANI Pharmaceuticals Reports Record Growth in Q2 2025

Ani Pharmaceuticals ( ($ANIP) ) has released its Q2 earnings. Here is a breakdown of the information Ani...

2M ago

ANIP

ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $93 from $84 and keeps a...

2M ago

ANIP

ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler

Piper Sandler analyst David Amsellem raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $94 from $80...

2M ago

ANIP

Morning Movers: Under Armour sinks following second quarter earnings

Stock futures are edging higher amid growing expectations that the Federal Reserve may move toward dovish policies, spurred...

2M ago

AMR

ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42

Reports Q2 revenue $211.4M, consensus $190.11M. “We had another record-setting quarter for our Company, with all-time highs in...

2M ago

ANIP

ANI Pharmaceuticals raises FY25 adj. EPS view to $6.98-$7.35 from $6.27-$6.62

FY25 consensus $6.51. Raises FY25 revenue view to $818M-$843M from $768M-$793M, consensus $791.48M. Raises FY25 adjusted EBITDA view...

2M ago

ANIP

Is ANIP a Buy, Before Earnings?

Ani Pharmaceuticals (ANIP) is scheduled to report 2nd quarter earnings on 08/08/2025, before the market opens. Regarding Q2...

2M ago

ANIP

ANIP FAQ

What was Ani Pharmaceuticals’s price range in the past 12 months?

Ani Pharmaceuticals lowest stock price was $52.50 and its highest was $99.50 in the past 12 months.

What is Ani Pharmaceuticals’s market cap?

Ani Pharmaceuticals’s market cap is $2.06B.

When is Ani Pharmaceuticals’s upcoming earnings report date?

Ani Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 40 days.

How were Ani Pharmaceuticals’s earnings last quarter?

Ani Pharmaceuticals released its earnings results on Aug 08, 2025. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.406 by $0.394.

Is Ani Pharmaceuticals overvalued?

According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ani Pharmaceuticals pay dividends?

Ani Pharmaceuticals does not currently pay dividends.

What is Ani Pharmaceuticals’s EPS estimate?

Ani Pharmaceuticals’s EPS estimate is 1.71.

How many shares outstanding does Ani Pharmaceuticals have?

Ani Pharmaceuticals has 21,688,772 shares outstanding.

What happened to Ani Pharmaceuticals’s price movement after its last earnings report?

Ani Pharmaceuticals reported an EPS of $1.8 in its last earnings report, beating expectations of $1.406. Following the earnings report the stock price went up 18.07%.

Which hedge fund is a major shareholder of Ani Pharmaceuticals?

Currently, no hedge funds are holding shares in ANIP

ANI Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-2.82%

Trailing 12-Months

Asset Growth

45.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ani Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals (ANIP) Earnings & Revenues

Historic Earnings Reports

ANIP Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth and successful product performances, particularly for Cortrophin Gel, along with raised financial guidance. However, it also acknowledged market access challenges in the retina segment and an ongoing legal dispute.View all ANIP earnings summaries

ANIP Stock 12 Month Forecast

Average Price Target

$103.50

▲(10.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"54":"$54","71":"$71","88":"$88","105":"$105","122":"$122"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$77.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[54,71,88,105,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.1,96.16923076923077,98.23846153846154,100.3076923076923,102.37692307692308,104.44615384615385,106.51538461538462,108.58461538461538,110.65384615384616,112.72307692307692,114.7923076923077,116.86153846153846,118.93076923076923,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.1,94.82307692307691,95.54615384615384,96.26923076923076,96.99230769230769,97.71538461538461,98.43846153846154,99.16153846153846,99.88461538461539,100.6076923076923,101.33076923076923,102.05384615384615,102.77692307692308,{"y":103.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.1,92.78461538461538,91.46923076923076,90.15384615384615,88.83846153846153,87.52307692307691,86.2076923076923,84.8923076923077,83.57692307692308,82.26153846153846,80.94615384615385,79.63076923076923,78.31538461538462,{"y":77,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >